Additionally, the combined use of SGLT2i with RASi is not only nephroprotective as shown in CREDENCE, DAPA‐CKD and subgroup analyses of CVOTs, but is associated with reduced rates of AKI, an effect seen in both the large trials and multiple observational cohorts.28, 29. This evidence concerns the gene MMP19 and chronic kidney disease.